Skip to main content

Drug Safety

audience learn
My favorite three presentations from day 4 at ACR 2021 included the following: Breakthrough Infections in Rheumatic Disease Patients Late-Breaking Abstract L16 - Dr. Jazvinder Singh presented the…
RT @swethaann23: Retrospective chart review of rheumatic irAE patients:

Persistent rheumatic irAE activity 🔼received

swethaann23 swethaann23

1 year ago
Retrospective chart review of rheumatic irAE patients: Persistent rheumatic irAE activity 🔼received GC Inflammatory arthritis pts 🔼risk of persistent rheumatic irAE Risk factors for mortality➡️tumor progression➕ continued Rx GC at last follow-up Abst#1516 #ACR21 @RheumNow https://t.co/KusNaVlEXp
RT @AkhilSoodMD: Abst 1517
Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI

Akhil Sood MD AkhilSoodMD

1 year ago
Abst 1517 Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI & developed rheumatic IRAE - Most common rheumatic IRAE = inflammatory arthritis - Higher prevalence of ANA in those tx w/ chemo prior to ICI #ACR21 @RheumNow https://t.co/7qgogSMjUr
EULAR19.abstract.jpg (keep)
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis. Abstract 1424 – Dr. Hermine…
switch.jpg
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? The NOR-DRUM trials (A and B) are the first randomized trials to assess…
×